Article
EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
Journal of cancer research and clinical oncology - 1 Aug 2013
Ito Yuriko, Yamada Yasuhide, Asada Kiyoshi, Ushijima Toshikazu, Iwasa Satoru, Kato Ken, Hamaguchi Tetsuya, Shimada Yasuhiro
Abstract excerpt
BACKGROUND: The KRAS mutation has been associated with resistance to cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in metastatic colorectal cancer (mCRC). However, the predictive biomarkers of cetuximab resistance in KRAS wild-type mCRC remain unknown except BRAF, NRAS, and PIK3CA exon 20. The objective of the study is to study the impact of EGFR L2 mutations on resistance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
